Antibody Response to Symptomatic Infection With SARS-CoV-2 Omicron Variant Viruses, December 2021-June 2022.
Ryan SandfordRuchi YadavEmma K NobleKelsey M SumnerDevyani JoshiSara Y TartofKaren J WernliEmily T MartinManjusha GaglaniRichard K ZimmermanH Keipp TalbotCarlos G GrijalvaEdward A BelongiaChristina CarlsonMelissa CoughlinBrendan FlanneryBrad PearceEric RogierPublished in: Influenza and other respiratory viruses (2024)
We describe humoral immune responses in 105 ambulatory patients with laboratory-confirmed SARS-CoV-2 Omicron variant infection. In dried blood spot (DBS) collected within 5 days of illness onset and during convalescence, we measured binding antibody (bAb) against ancestral spike protein receptor binding domain (RBD) and nucleocapsid (N) protein using a commercial multiplex bead assay. Geometric mean bAb concentrations against RBD increased by a factor of 2.5 from 1258 to 3189 units/mL and by a factor of 47 against N protein from 5.5 to 259 units/mL between acute illness and convalescence; lower concentrations were associated with greater geometric mean ratios. Paired DBS specimens may be used to evaluate humoral response to SARS-CoV-2 infection.